LINC01833: A Long Intergenic Non-Protein Coding RNA and Its Potential as a Drug Target

Target Name: LINC01833

NCBI ID: G107985879

LINC01833

Other Name(s): Long intergenic non-protein coding RNA 1833, transcript variant 1 | RP11-89 | K21.1 | long intergenic non-protein coding RNA 1833

LINC01833: A Long Intergenic Non-Protein Coding RNA and Its Potential as a Drug Target

LINC01833 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique structure that consists of a series of exons, which are arranged in a specific order to create a unique RNA molecule. Unlike protein-coding RNAs, lncRNAs are not translated into proteins, but rather they have different functions in the cell. In this article, we will explore the potential of LINC01833 as a drug target and its potential uses in the future.

Understanding LINC01833

LINC01833 is a transcribed RNA molecule that contains a unique sequence of nucleotides. It is approximately 180 nucleotides in length and has a molecular weight of approximately 4.8 kDa. LINC01833 is expressed in various tissues and cells in the body, including the brain, heart, and liver.

The structure of LINC01833 is unique because it is not a simple linear molecule. Instead, it has a complex structure that includes a stem-loop, a 5'-end insertion loop, and a 3'-end extension. The stem-loop is a repeating sequence that is found in the middle of the molecule, while the 5'-end insertion loop is located at the beginning of the molecule. The 3'-end extension is located at the end of the molecule.

Function of LINC01833

LINC01833 is involved in various cellular processes in the body. One of its functions is to regulate gene expression. It interacts with the RNA polymerase II complex, which is responsible for transcribing DNA into RNA. By interacting with the RNA polymerase II complex, LINC01833 can influence the expression of genes that are important for the cell's survival and growth.

Another function of LINC01833 is to regulate microRNA (miRNA) expression. miRNA are small non-coding RNAs that play a critical role in post-transcriptional gene regulation. LINC01833 can interact with the miRNA machinery to regulate the expression of miRNAs that are important for the cell's survival and growth.

Drug Target Potential

The potential of LINC01833 as a drug target is due to its unique structure and its involvement in various cellular processes. LINC01833 has been shown to interact with various drug targets, including the protein p21, which is a known inhibitor of the cell cycle.

In addition, LINC01833 has also been shown to interact with the protein p53, which is a well-known regulator of the DNA damage response. LINC01833 can interact with p53 and enhance its activity, which may have implications for the regulation of cell growth and the development of cancer.

Potential Uses

The potential uses of LINC01833 as a drug target are vast. One of the most promising potential uses is for the treatment of cancer. LINC01833 has been shown to be involved in the regulation of cell cycle progression and has been shown to interact with various drug targets that are important for cancer cell survival.

Another potential use of LINC01833 as a drug target is for the treatment of neurodegenerative diseases. LINC01833 has been shown to be involved in the regulation of protein synthesis and has been shown to interact with various neurotransmitter receptors that are important for neurotransmission.

Conclusion

In conclusion, LINC01833 is a unique RNA molecule that has been identified in various organisms

Protein Name: Long Intergenic Non-protein Coding RNA 1833

The "LINC01833 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01833 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets